Page last updated: 2024-10-15

5,8-dideazaisofolic acid

Description

5,8-dideazaisofolic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135449342
CHEMBL ID3244861
MeSH IDM0108806

Synonyms (10)

Synonym
56239-21-5
5,8-dideazaisofolic acid
iahq
nsc-285571
5,8-dideazaisopteroylglutamate
nsc 289517
l-glutamic acid, n-(4-(((2-amino-1,4-dihydro-4-oxo-6-quinazolinyl)amino)methyl)benzoyl)-
CHEMBL3244861
TQR0515
(s)-2-(4-(((2-amino-4-oxo-1,4-dihydroquinazolin-6-yl)amino)methyl)benzamido)pentanedioic acid

Compound-Compound Interactions

ExcerptReference
"3 microM dThd was sufficient to completely protect sensitive cells from 5-fluoro-2'-deoxyuridine, and 5,8-dideazaisofolic acid at concentrations that produced over 80% lethality in unprotected cells and the same concentration of dThd in combination with 100 microM hypoxanthine fully protected sensitive cells from greater than 99% methotrexate-induced cell lethality."( Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine.
Bertino, JR; Handschumacher, RE; Sobrero, AF, 1985
)
" Since IAHQ has only modest activity against L1210 leukemia in mice, it was tested in combination with methotrexate (MTX), probenecid, or verapamil in an effort to enhance efficacy."( Effects of 5,8-dideazaisopteroylglutamate (IAHQ) on L1210 leukemia in mice when given alone and in combination with methotrexate, probenecid, or verapamil.
Gale, GR; Hynes, JB; Smith, AB, 1986
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseEnterococcus faeciumIC50 (µMol)22.00000.00140.67711.6000AID1134002
Cytochrome P450 11B1, mitochondrial Bos taurus (cattle)IC50 (µMol)13.28400.00101.06087.8300AID1134001; AID1134002
Histidine decarboxylaseRattus norvegicus (Norway rat)IC50 (µMol)22.00000.00140.67711.6000AID1134002
Dihydrofolate reductaseRattus norvegicus (Norway rat)IC50 (µMol)0.21000.00060.35076.2000AID1134001
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
glucocorticoid biosynthetic processCytochrome P450 11B1, mitochondrial Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
iron ion bindingCytochrome P450 11B1, mitochondrial Bos taurus (cattle)
heme bindingCytochrome P450 11B1, mitochondrial Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1134001Inhibition of rat liver dihydrofolate reductase using dihydrofolate as substrate1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Quinazolines as inhibitors of dihydrofolate reductase. 4. Classical analogues of folic and isofolic acids.
AID1134002Inhibition of Streptococcus faecium dihydrofolate reductase using dihydrofolate as substrate1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Quinazolines as inhibitors of dihydrofolate reductase. 4. Classical analogues of folic and isofolic acids.
AID1145385Inhibition of liver dihydrofolate reductase (unknown origin)1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Inhibition of dihydrofolate reductase. Structure-activity correlations of quinazolines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (72.22)18.7374
1990's5 (27.78)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]